An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma

@inproceedings{Yoon2019AnRA,
  title={An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFRα Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma},
  author={Sorah Yoon and Xiwei Wu and Brian Armstrong and N Habib and John J. Rossi},
  booktitle={Molecular therapy. Nucleic acids},
  year={2019}
}
Human glioblastoma (GBM) is the most aggressive malignancy of the CNS, with less than 5% survival. Despite great efforts to find effective therapeutics, current options remain very limited. To develop a targeted cancer therapeutic, we selected RNA aptamers against platelet-derived growth factor receptor α (PDGFRα), which is a receptor tyrosine kinase. One RNA aptamer (PDR3) with high affinity (0.25 nM) showed PDGFRα specificity and was internalized in U251-MG cells. Following treatment with the… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 69 REFERENCES

Platelet-derived growth factor in glioblastoma—driver or biomarker?

  • Upsala journal of medical sciences
  • 2014
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

Validating Stat3 in cancer therapy

  • Nature Medicine
  • 2005
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

The STATs of cancer — new molecular targets come of age

Hua Yu, Richard Jove
  • Nature Reviews Cancer
  • 2004
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL

An introduction to death receptors in apoptosis.

  • International journal of surgery
  • 2005
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL